Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A highly effective new treatment for multiple sclerosis was approved yesterday by the European Medicines Agency, the regulator for drugs in Europe.

The drug can offer people with early multiple sclerosis many more years free from worsening disability, and Oxford played an important role in the drug's development.

Professor Herman Waldmann was involved in the early discovery work with the antibody drug at Cambridge University and brought a significant proportion of the research to Oxford when he moved here in 1994.

Read more

Related news item: NICE approve Waldmann's MS drug for use in UK hospitals